BioLife Solutions Inc. (BULLETIN BOARD: BLFS) announced today that it has reached a key milestone in its strategy to begin positioning the Company for future sales growth with the signing of a two-year manufacturing agreement with Herndon, VA-based Mediatech, Inc., a leading manufacturer of cell culture media and reagents. Mediatech will be the primary manufacturer for BioLife's Hypothermosol® family of preservation solutions.

BioLife President and CEO John G. Baust, Ph.D., said, "As we increase our focus on developing new business and revenue streams, an outsourced manufacturing solution makes perfect sense for our organization. With its state-of-the-art, sterile-fill production facility and decades of experience in 'solutions' manufacturing, Mediatech can provide us a reliable source of high quality product and help us control our costs, which is important at this stage of our development. By outsourcing our manufacturing we are also able to concentrate our resources where they can bring the greatest returns in the near term.

"Mediatech is highly regarded within the international cell-based biomedical community for its reliability and quality products and we are pleased to formalize our relationship," Baust added. "Mediatech has begun manufacturing Hypothermosol, with first shipments to occur this month."

Founded in 1984, Mediatech provides the scientific research and biopharmaceutical production communities with superior products and outsourced manufacturing services. Manufacturing of BioLife's Hypothermosol products by Mediatech will follow current Good Manufacturing Practices (cGMPs) prescribed by the FDA.

About BioLife Solutions, Inc.

BioLife Solutions has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on the Company's proprietary bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. The expanding practice of cell and gene therapy has created a need for products that ensure the biological viability of mammalian cell and tissue material during transportation and storage. The HypoThermosol® and CryoStor™ products that the Company is selling today are a significant step forward in meeting these needs.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

For further information please contact Investors, Jill Bertotti, jill@allencaron.com , or Media, Len Hall, len@allencaron.com , both of Allen & Caron Inc, +1-949-474-4300, for BioLife Solutions Inc.

SOURCE: BioLife Solutions Inc.